- (3) for treating another dermatological condition/affliction associated with a keratinization disorder manifesting an inflammatory and/or immunoallergenic component, or for treating inflammatory conditions which manifest no keratinization disorder, or
- (4) for treating all dermal or epidermal proliferations, whether benign or malignant and whether of viral or non-viral origin, or
 - (5) for treating bullosis or a collagen disease state, or
- (6) for repairing or combating aging of the skin, whether photoinduced or chronological aging, or for reducing pigmentations and actinic keratosis, or any pathology associated with chronological or actinic aging, or
- (7) for curing the stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or other form of cutaneous atrophy, or
- (8) for the curative treatment of cicatrization disorders, for repairing stretch marks, or for promoting cicatrization, or
 - (9) for combating disorders of sebaceous functioning, or
 - (10) for the curative treatment of cancerous or precancerous disease states, or
 - (11) for the treatment of inflammatory conditions/afflictions, or
 - (12) for the treatment of any skin condition/affliction of viral origin, or
 - (13) for the curative treatment of alopecia, or
- (14) for the treatment of dermatological conditions/afflictions manifesting an immunological component, or
 - (15) for the treatment of skin disorders caused by exposure to UV radiation, or

con-

Application No. <u>09/881,686</u> Attorney's Docket No. <u>016800-445</u>

Page 3

- (16) for the treatment of dermatological conditions/afflictions associated with inflammation or infection of the tissues surrounding the hair follicles, or
- (17) for accelerating or promoting hair loss, comprising topically applying onto the skin, scalp and/or hair of a candidate subject in need of such treatment, for such period of time as required to elicit the desired biological response, a topically applicable cosmetic/pharmaceutical oil-in-water emulsion including a discontinuous fatty phase dispersed in a continuous aqueous phase and comprising an effective amount of at least one thus-biologically active agent (A) and an effective amount of an emulsifying system (B) therefor, said at least one biologically active agent (A) being non-solubilized therein in micronized particulate state, at least 80%, numerically, of said micronized particles having diameters ranging from 1 to 10 μ m and at least 50%, also numerically, having diameters of less than 5 μ m.
- 42. (Amended) The regime/regimen as defined by Claim 41, comprising curatively treating acne.

Please add new Claim 50.

- 50. (New) A regime or regimen:
- (1) for treating common acne, comedones, polymorphonuclear leukocytes, rosacea, nodulocystic acne, acne conglobata, senile acne and secondary acne, or solar, medication-related or occupational acne, or

but c'y

- (2) for treating ichtyosis, an ichtyosiform state, Darier's disease, palmoplantar keratoderma, leukoplasia, a leukoplasiform state, or cutaneous or mucous (buccal) lichen, or
- (3) for treating all forms of psoriasis, whether cutaneous, mucous or ungual psoriasis, psoriatic rheumatism, cutaneous atopy, eczema, respiratory atopy, gingival hypertrophy, or for treating rosacea, or
- (4) for treating common warts, flat warts, verruciform epidermodysplasia, oral or florid papillomatoses or proliferations induced by ultraviolet radiation, basocellular or spinocellular epithelioma, or
 - (5) for treating bullosis or a collagen disease state, or
- (6) for repairing or combating aging of the skin, whether photoinduced or chronological aging, or for reducing pigmentations and actinic keratosis, or any pathology associated with chronological or actinic aging, or
- (7) for curing the stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or other form of cutaneous atrophy, or
- (8) for the curative treatment of cicatrization disorders, for repairing stretch marks, or for promoting cicatrization, or
 - (9) for combating acneic hyperseborrhoea or simple seborrhoea, or
 - (10) for the curative treatment of cancerous or predancerous disease states, or
 - (11) for the treatment of arthritis, or
 - (12) for the treatment of any skin condition/affliction of viral origin, or
 - (13) for the curative treatment of alopecia, or

In Cont

A . 5711.

Application No. <u>09/881,686</u> Attorney's Docket No. <u>016800-445</u> Page 5

- (14) for the treatment of derma ological conditions/afflictions manifesting an immunological component, or
 - (15) for the treatment of skin disorders caused by exposure to UV radiation, or
- (16) for the treatment of colonization or mocrobial infection, impetigo, seborrhoeic dermatitis, folliculitis, sycosis barbae, or
- (17) for accelerating or promoting hair loss, comprising topically applying onto the skin, scalp and/or hair of a candidate subject in need of such treatment, for such period of time as required to elicit the desired biological response, a topically applicable cosmetic/pharmaceutical oil-in-water emulsion including a discontinuous fatty phase dispersed in a continuous aqueous phase and comprising an effective amount of at least one thus-biologically active agent (A) and an effective amount of an emulsifying system (B) therefor, said at least one biologically active agent (A) being non-solubilized therein in micronized particulate state, at least 80%, numerically, of said micronized particles having diameters ranging from 1 to 10 μ m and at least 50%, also numerically, having diameters of less than 5 μ .

July 22

cont.